Comparison of Three-dimensional and Two-dimensional Left Ventricle Strain With Speckle-tracking Echocardiography in Heart Failure With Reduced and Mildly Reduced Ejection Fraction (3V2-STEM-HF)
Left Ventricular Myocardial Strain Assessed by Three-dimensional Speckle-tracking Echocardiography in Heart Failure With Reduced and Mildly Reduced Ejection Fraction. A Comparison With Two-dimensional Evaluation in a Prospective Study
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Detailní popis
Left Ventricular Myocardial Strain Assessed by Three-Dimensional Speckle-Tracking Echocardiography in Heart Failure with Reduced or Mildly Reduced Ejection Fraction: Comparison with Two-Dimensional Assessment in a Prospective Observational Study
Background
Global longitudinal strain (GLS) derived from speckle-tracking echocardiography (STE) is a robust, well-validated, and reproducible technique for assessing left ventricular (LV) longitudinal deformation and is available on most modern echocardiography systems. GLS appears to provide superior prognostic value compared with ejection fraction (EF) for predicting major adverse cardiac events across various clinical settings, including chronic heart failure (CHF).
Three-dimensional (3D) STE represents a further advancement in myocardial deformation imaging, enabling rapid and comprehensive assessment of all LV segments and measurement of global 3D GLS from a single dataset. However, in healthy individuals, reference values for 3D and 2D GLS differ significantly, likely because 3D GLS more accurately captures the complex mechanics of LV contraction, whereas 2D GLS provides higher spatial and temporal resolution.
Although 3D STE is increasingly being used to evaluate LV systolic function in patients with CHF, data regarding the agreement and differences between 2D and 3D measurements in this clinical setting remain limited. This issue is particularly relevant in patients with systolic heart failure, as reduced EF appears to weaken the correlation between 2D and 3D GLS measurements, according to available studies with relatively small sample sizes.
Objectives
This prospective multicenter study aims to evaluate the agreement between 2D and 3D GLS measurements obtained using single-vendor ultrasound systems and analysis software in patients with heart failure with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF).
Secondary objectives are to identify factors associated with differences between 2D and 3D GLS measurements and to determine whether 3D GLS is a stronger independent predictor of all-cause mortality than 2D GLS.
Methods Study Population
This multicenter prospective observational study will enroll patients with HFrEF and HFmrEF, defined as a left ventricular ejection fraction (LVEF) ≤40% and 41-49%, respectively, from the echocardiography laboratories of the Cardiovascular Department of Istituti Clinici Scientifici (ICS) Maugeri across seven tertiary cardiac rehabilitation hospitals in Italy.
The study protocol has been approved to the local Ethics Committee. Written informed consent will be obtained from all participants before eligibility screening.
Image Acquisition and Analysis
Echocardiographic datasets will be acquired using Vivid E95 ultrasound systems (GE Vingmed Ultrasound AS, Horten, Norway) equipped with M5S and 4V probes for 2D and 3D imaging, respectively, or a 4VC probe for both 2D and 3D acquisitions.
The acquisition protocol will include 2-, 3-, and 4-chamber apical views, as well as parasternal short-axis views at the mid-papillary level for 2D imaging, together with 3D LV datasets for the assessment of myocardial strain parameters using 2D and 3D STE. If necessary, two- to six-beat full-volume 3D acquisitions will be performed to ensure complete LV coverage with a frame rate of at least 37 volumes/s.
Two-dimensional and three-dimensional datasets will be analyzed offline using the Q-Analysis and 4D AutoLVQ software packages (EchoPAC BT12 and BT13; GE Vingmed Ultrasound AS) by investigators with at least three years of experience.
Peak global 2D longitudinal strain (2DLε) will be calculated from the three apical views, whereas peak global 2D circumferential strain (2DCε) will be derived from the parasternal short-axis view. Three 3D strain parameters will be obtained from the 3D LV dataset: longitudinal strain (3DLε), circumferential strain (3DCε), radial strain (3DRε), and area strain (3DAε).
Datasets will be excluded from analysis under the following conditions:
- poor image quality of either the 2D or 3D datasets, defined using a 4-point scale (poor = 1, fair = 2, good = 3, excellent = 4) because of inadequate signal-to-noise ratio, poor blood-tissue contrast, stitching artifacts or incomplete visualization of the LV wall;
- inadequate tracking of more than two LV segments in a single apical 2D view for global 2DLε analysis or in the parasternal short-axis view for 2DCε and 2DRε analysis;
- inadequate tracking of more than three LV segments during 3D dataset analysis.
Sample Size
Agreement between 2D and 3D GLS measurements will be assessed using Bland-Altman analysis. Based on published data reporting a mean difference of 0.1% and a standard deviation of differences of 2.9%, the required sample size was calculated to be 419 participants, assuming a maximum acceptable difference between methods of ±6.5%, a type I error (α) of 5%, and a type II error (β) of 20%.
Statistical Analysis
Normally distributed continuous variables will be summarized as mean ± standard deviation (SD), whereas non-normally distributed continuous variables will be reported as median and interquartile range (IQR). Categorical variables will be expressed as counts and percentages.
All LV strain parameters will be analyzed as absolute values, with lower values indicating worse myocardial deformation and higher values indicating better deformation.
Differences between groups will be assessed using unpaired t-tests for normally distributed variables and Mann-Whitney U tests for non-normally distributed variables. Agreement between 2D and 3D LV strain measurements will be evaluated using Bland-Altman analysis. Differences between paired 2D and 3D strain measurements within predefined subgroups will be assessed using paired statistical tests, as appropriate.
Pearson correlation analysis will be used to evaluate associations between the differences in 2D and 3D GLS measurements and demographic, cardiac, and technical variables. Stepwise multivariable linear regression analysis will be performed to identify independent predictors of the differences between 2D and 3D GLS measurements, including age, sex, weight, height, blood pressure, body surface area (BSA), LV volumes, LV mass, temporal resolution, and 3D image quality.
The area under the receiver operating characteristic curve (AUC-ROC) will be used to assess the predictive performance of 2D and 3D GLS for all-cause mortality. The DeLong test will be used to compare the AUCs of the two methods.
All hypothesis tests will be two-sided, and a p-value <0.05 will be considered statistically significant. Statistical analyses will be performed using SPSS software (IBM, Armonk, NY, USA).
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Oronzo Catalano, MD
- Telefonní číslo: +39(0)382592608
- E-mail: oronzo.catalano@icsmaugeri.it
Studijní záloha kontaktů
- Jméno: Miriam De Giorgi, DMS
- Telefonní číslo: +39(0)382592982
- E-mail: miriam.degiorgi@icsmaugeri.it
Studijní místa
-
-
-
Veruno, Itálie, 28013
- Nábor
- ICS Maugeri - Istituto di Veruno
-
Kontakt:
- Fabiana Gambarin, MD
- Telefonní číslo: +39(0)322884711
- E-mail: fabiana.gambarin@icsmaugeri.it
-
-
BA
-
Bari, BA, Itálie, 70124
- Nábor
- ICS Maugeri - Istituto di Bari
-
Kontakt:
- Caterina Rizzo, MD
- Telefonní číslo: +39(0)807814111
- E-mail: caterina.rizzo@icsmaugeri.it
-
Kontakt:
- Andrea Passantino, MD
- Telefonní číslo: +39(0)807814111
- E-mail: andrea.passantino@icsmaugeri.it
-
-
MI
-
Milan, MI, Itálie, 20138
- Nábor
- ICS Maugeri - Istituto di Milano
-
Kontakt:
- Edvige Palazzo Adriano, MD
- Telefonní číslo: +39(0)2507259
- E-mail: edvige.palazzoadriano@icsmaugeri.it
-
-
PV
-
Pavia, PV, Itálie, 27100
- Nábor
- ICS Maugeri - Istituto di Pavia
-
Kontakt:
- Miriam De Giorgi, DMS
- Telefonní číslo: +39(0)382592982
- E-mail: miriam.degiorgi@icsmaugeri.it
-
Kontakt:
- Oronzo Catalano, MD PI
- Telefonní číslo: +39(0)382592982
- E-mail: oronzo.catalano@icsmaugeri.it
-
-
TO
-
Torino, TO, Itálie, 10124
- Nábor
- ICS Maugeri Torino
-
Kontakt:
- Franco Tarro Genta, MD
- Telefonní číslo: +39(0)118151611
- E-mail: franco.tarrogenta@icsmaugeri.it
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Left ventricular ejection fraction (LVEF) ≤ 49%;
- Echocardiographic image quality judged to be at least adequate according to a four-point visual image quality scale (good, adequate, poor, or inadequate)
Exclusion Criteria:
- Inability to maintain the correct position for acquiring echocardiographic images;
- Arrhythmias that make multi-beat acquisition impossible (if required), such as frequent extrasystoles (supraventricular or ventricular) and atrial fibrillation;
- Failure to visualize more than 2 segments of the left ventricle (LV), or inability to assess more than 3 segments during 3D GLS analysis;
- Failure to sign the informed consent form and inability of the participant to understand the objectives of the study
Studijní plán
Jak je studie koncipována?
Detaily designu
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
|---|
|
Heart failure with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF)
Patients with HFrEF or EFmrEF will be assessed with 2D and 3D echocardiography to evaluate the agreement between 2D and 3D global longitudinal strain measurements
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Bland-Altman mean difference (bias) and the limits of agreement (LOA) in comparison with a clinically acceptable range (±6.5%)
Časové okno: At baseline
|
Bias and the LOA will be compared with a clinically acceptable range (±6.5%)
|
At baseline
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Covariates and Confounders
Časové okno: At baseline
|
The factors associated with differences between 2D and 3D GLS measurements
|
At baseline
|
|
Comparison of all-cause mortality by 2D and 3D global longitudinal strain
Časové okno: From enrollment to the end of follow-up (1 year)
|
The area under the receiver operating characteristic curve (AUC-ROC) will be used to assess the predictive performance of 2D and 3D GLS for all-cause mortality.
The DeLong test will be used to compare the AUCs of the two methods.
|
From enrollment to the end of follow-up (1 year)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- Saito K, Okura H, Watanabe N, Hayashida A, Obase K, Imai K, Maehama T, Kawamoto T, Neishi Y, Yoshida K. Comprehensive evaluation of left ventricular strain using speckle tracking echocardiography in normal adults: comparison of three-dimensional and two-dimensional approaches. J Am Soc Echocardiogr. 2009 Sep;22(9):1025-30. doi: 10.1016/j.echo.2009.05.021. Epub 2009 Jun 24.
- Muraru D, Cucchini U, Mihaila S, Miglioranza MH, Aruta P, Cavalli G, Cecchetto A, Padayattil-Jose S, Peluso D, Iliceto S, Badano LP. Left ventricular myocardial strain by three-dimensional speckle-tracking echocardiography in healthy subjects: reference values and analysis of their physiologic and technical determinants. J Am Soc Echocardiogr. 2014 Aug;27(8):858-871.e1. doi: 10.1016/j.echo.2014.05.010. Epub 2014 Jun 26.
- Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014 Nov;100(21):1673-80. doi: 10.1136/heartjnl-2014-305538. Epub 2014 May 23.
- Hjertaas JJ, Fossa H, Dybdahl GL, Gruner R, Lunde P, Matre K. Accuracy of real-time single- and multi-beat 3-d speckle tracking echocardiography in vitro. Ultrasound Med Biol. 2013 Jun;39(6):1006-14. doi: 10.1016/j.ultrasmedbio.2013.01.010. Epub 2013 Apr 3.
- Geyer H, Caracciolo G, Abe H, Wilansky S, Carerj S, Gentile F, Nesser HJ, Khandheria B, Narula J, Sengupta PP. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr. 2010 Apr;23(4):351-69; quiz 453-5. doi: 10.1016/j.echo.2010.02.015.
- Aly D, Madan N, Kuzava L, Samrany A, Parthiban A. Comprehensive evaluation of left ventricular deformation using speckle tracking echocardiography in normal children: comparison of three-dimensional and two-dimensional approaches. Cardiovasc Ultrasound. 2022 Jan 27;20(1):3. doi: 10.1186/s12947-022-00273-6.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- CTSM165-25
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Časový rámec sdílení IPD
Kritéria přístupu pro sdílení IPD
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .